FDA review practices and priorities for drugs used in cancer treatment
Kobayashi K, DeLap RJ
Published December 2001 Annals of the New York Academy of Sciences, 949(1), 341-344
Cite this paper
Kobayashi, K., & DeLap, R. J. (2001). FDA review practices and priorities for drugs used in cancer treatment. Annals of the New York Academy of Sciences, 949(1), 341-344. https://doi.org/10.1111/j.1749-6632.2001.tb04042.x
Kobayashi K, DeLap RJ. FDA review practices and priorities for drugs used in cancer treatment. Annals of the New York Academy of Sciences. 2001;949(1):341-344. doi:10.1111/j.1749-6632.2001.tb04042.x
Kobayashi, K., and R. J. DeLap. "FDA review practices and priorities for drugs used in cancer treatment." Annals of the New York Academy of Sciences, vol. 949, no. 1, 2001, pp. 341-344.
For EndNote, Zotero or Mendeley:
License
Open-access status not yet checked.


